Stocks and Investing Stocks and Investing
Mon, June 26, 2023
Fri, June 23, 2023

Matthew Harrison Reiterated (SRPT) at Buy and Held Target at $183 on, Jun 23rd, 2023


Published on 2024-10-28 04:29:18 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $183 on, Jun 23rd, 2023.

Matthew has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Matthew


  • Hartaj Singh of "Oppenheimer" Reiterated at Buy and Held Target at $180 on, Friday, May 26th, 2023
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $173 on, Monday, May 15th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $176 on, Monday, May 15th, 2023
  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $185 on, Wednesday, April 26th, 2023
  • Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Friday, April 14th, 2023
  • Ritu Baral of "TD Cowen" Maintained at Buy with Increased Target to $175 on, Wednesday, March 22nd, 2023
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Wednesday, March 1st, 2023
Contributing Sources